National Research (NRC) Set to Post Earnings on Monday

Key Points

• National Research is expected to report Q3 2026 results after Monday’s market close. Analysts anticipate earnings of $0.21 per share on revenue of $35.80 million, with the earnings call scheduled for Tuesday, October 27.
• The company exceeded expectations in its prior quarter, reporting $0.31 EPS and $35.39 million in revenue versus estimates of a $0.15 per-share loss and $34.90 million in revenue.
• Analyst sentiment is mixed, with the stock carrying a consensus “Hold” rating and a $26 price target. Shares recently opened at $20.15, compared with a 52-week range of $11.32 to $23.68.

National Research (NASDAQ:NRC - Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Monday, October 26th. Analysts expect National Research to post earnings of $0.21 per share and revenue of $35.80 million for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 4:30 PM ET.

National Research (NASDAQ:NRC - Get Free Report) last issued its earnings results on Tuesday, July 28th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.46. National Research had a net margin of 4.18% and a return on equity of 164.26%. The company had revenue of $35.39 million for the quarter, compared to analysts' expectations of $34.90 million. On average, analysts expect National Research to post $0.98 EPS for the current fiscal year and $1.05 EPS for the next fiscal year.

National Research Stock Performance

Shares of NASDAQ:NRC opened at $20.15 on Monday. National Research has a 52-week low of $11.32 and a 52-week high of $23.68. The company has a market capitalization of $458.41 million, a P/E ratio of 80.60 and a beta of 0.25. The company has a 50-day simple moving average of $21.11 and a 200 day simple moving average of $19.96. The company has a debt-to-equity ratio of 13.13, a quick ratio of 0.65 and a current ratio of 0.65.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Wall Street Zen downgraded National Research from a "buy" rating to a "hold" rating in a research report on Saturday, August 15th. Weiss Ratings lowered National Research from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, October 9th. Zacks Research raised National Research to a "hold" rating in a research report on Monday, October 5th. Finally, Citizens Jmp raised their price objective on National Research from $23.00 to $26.00 and gave the company a "market outperform" rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $26.00.

National Research Company Profile

National Research Corporation, formerly traded on the Nasdaq under the symbol NRC and known as NRC Health, provides market research, analytics and performance-improvement services to healthcare organizations. Its solutions are designed to help hospitals, health systems and other providers understand the experiences and expectations of patients, employees, physicians and communities.

The company's offerings have included patient-experience measurement, employee and physician engagement surveys, reputation and brand research, community health assessments, data analytics and advisory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.